Motol University Hospital is a large teaching hospital in the Motol area of Prague. It is the largest medical facility in the Czech Republic and one of the largest in Europe.

There are 2,410 beds in Fakultni nemocnice v Motole.

During the past decade, Fakultni nemocnice v Motole conducted 154 clinical trials. In the 10-year time frame, 154 clinical trials started and 74 clinical trials were completed, i.e. on average, 48.1% percent of trials that started reached the finish line to date. In the past 5 years, 68 clinical trials started and 51 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fakultni nemocnice v Motole" #1 sponsor was "Pfizer" with 13 trials, followed by "Baxalta now part of Shire" with 7 trials sponsored, "Bayer" with 7 trials sponsored, "Boehringer Ingelheim" with 7 trials sponsored and "Eli Lilly and Company" with 7 trials sponsored. Other sponsors include 179 different institutions and companies that sponsored additional 122 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fakultni nemocnice v Motole" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Brno University Hospital" with 3 trials as a collaborator, "Incyte Corporation" with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator and "University Hospital, Motol" with 3 trials as a collaborator. Other collaborators include 172 different institutions and companies that were collaborators in the rest 163 trials.

According to Clinical.Site data, the most researched conditions in "Fakultni nemocnice v Motole" are "Cystic Fibrosis" (13 trials), "Multiple Sclerosis" (6 trials), "Hemophilia A" (5 trials), "Leukemia" (5 trials) and "Atopic Dermatitis" (4 trials). Many other conditions were trialed in "Fakultni nemocnice v Motole" in a lesser frequency.

Most popular intervention types in "Fakultni nemocnice v Motole" are "Drug" (165 trials), "Biological" (33 trials), "Other" (23 trials), "Procedure" (15 trials) and "Device" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (46 trials), "placebo" (7 trials), "IVA" (6 trials), "Baricitinib" (5 trials) and "Etoposide" (5 trials). Other intervention names were less common.

The vast majority of trials in "Fakultni nemocnice v Motole" are 202 trials for "All" genders, 18 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Fakultni nemocnice v Motole". undefined are not yet recruiting, 52 are recruiting, 29 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 107 completed trials in Fakultni nemocnice v Motole, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Fakultni nemocnice v Motole, 12 "Phase 1" clinical trials were conducted, 59 "Phase 2" clinical trials and 119 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 13 trials that are defined as “Not Applicable".

Fakultni nemocnice v Motole has several departments that took part in Clinical trials: "Fakultni nemocnice v Motole; Onkologicka klinika 2. LF UK a FN Motol" - 9 trials, "Fakultni nemocnice Motol; Neurologicka klinika" - 4 trials, "Department of Rehabilitation and Sports Medicine, University Hospital Motol" - 3 trials, "University Hospital Motol, Clinic of Oncology" - 2 trials, "Fakultni nemocnice v Motole; Neurologicka klinika 2. LF UK a FN Motol" - 2 trials, "Department of neurology" - 2 trials, "Teaching Hospital Motol, Oncology Clinic" - 2 trials, "Department of Cardiology, University Hospital Motol" - 2 trials, "Fakultní nemocnice v Motole, dětské kardiocentrum - Site 3301" - 2 trials, "University Hospital Motol; Department of Urology" - 2 trials